PeptidesEvidence ReviewAug 2026

Best Peptides for Injury Healing in 2026

For each peptide tied to injury and wound repair, this page reports the studies behind it: who was enrolled, what was measured, what the paper found. Every citation was retrieved through NCBI E-utilities on 9 August 2026. Some trials treated diabetic ulcers, some treated tendons, and several were run in animals. A wound, an ulcer or a torn tendon is diagnosed and managed with a clinician, and the population column is where each result is pinned to the people or animals it came from.

216

Adults in the PDRN diabetic foot ulcer trial (PMID 24483158)

Athletes in the collagen ankle-instability trial (PMID 29769831)

Subjects in the thymosin beta-4 dry eye trial (PMID 26056426)

The Studies

One row per study, not one per compound. A compound studied several times gets several rows, because those papers asked different questions in different populations. Read the population and design columns before the result.

Compound	Population (n)	What was measured	Result	Design	PMID
Polydeoxyribonucleotide (PDRN)	216 adults with Wagner grade 1 or 2 chronic diabetic foot ulcers at two Italian centres	Complete ulcer healing and time to closure over 8 weeks	Complete healing 37.3 percent (95 percent CI 28.2 to 46.3) versus 18.9 percent (11.4 to 26.3) on placebo, P = .0027; median time 30 versus 49 days; hazard ratio 2.20 (1.29 to 3.75)	Randomised double-blind placebo-controlled, intramuscular and perilesional	24483158
Polydeoxyribonucleotide (PDRN)	20 patients with a non-healing diabetic foot ulcer, 10 per arm	Transcutaneous oxygen tension and vessel density around the ulcer	Tissue oxygenation higher than control at days 7, 14 and 28 (P below .01 to P below .001); vessel density not different (P = .094)	Prospective randomised controlled trial, intramuscular and perilesional	29076318
Polydeoxyribonucleotide (PDRN)	23 patients with pressure ulcers, 11 on PDRN and 12 control	Wound surface area and the PUSH pressure-ulcer healing score at 4 weeks	Wound size and PUSH score both fell versus control after 4 weeks, with no adverse effect reported	Randomised controlled trial, intramuscular and perilesional	25473213
Polydeoxyribonucleotide (PDRN)	106 patients with chronic refractory rotator cuff disease, 55 on PDRN and 51 conservative care	Shoulder Pain and Disability Index, pain VAS, strength, range of motion, ultrasonographic tear size	Pain index, VAS and daily analgesic use improved versus control; isometric strength, range of motion and tear size unchanged	Case-controlled retrospective comparative study, 6-month follow-up	27914921
Polydeoxyribonucleotide (PDRN)	63 patients with chronic lateral epicondylitis in three arms	Mayo Elbow Performance Score and common extensor tendon depth on ultrasound	Performance score and tendon depth rose more with PDRN plus exercise than exercise alone at 6 and 12 weeks	Randomised controlled trial, three arms	34823312
Polydeoxyribonucleotide (PDRN)	123 cases with tendon or ligament pain, pooled from one randomised and three retrospective studies	Pain on a standardised mean difference across the pooled studies	Pain fell after PDRN injection, standardised mean difference -1.43 (95 percent CI -1.80 to -1.06, P below .00001)	PRISMA-compliant meta-analysis	34106615
Specific collagen peptides	20 patients with chronic mid-portion Achilles tendinopathy, all on a calf-strengthening program	VISA-A tendon-function questionnaire and tendon microvascularity	VISA-A rose 12.6 points (9.7 to 15.5) over the first 3 months on collagen versus 5.3 (2.3 to 8.3) on placebo	Randomised placebo-controlled crossover, 6 months	30609761
Collagen peptide type-1, with chondroitin, hyaluronate and vitamin C	40 patients with Achilles tendinopathy randomised to the combination or oral diclofenac	Pain VAS and tendon thickness on ultrasound over 12 weeks	The combination reduced VAS pain more than diclofenac at 12 weeks; both reduced tendon thickness	Prospective randomised controlled trial	34812335
Specific collagen peptides	50 male and female athletes with chronic ankle instability	CAIT and FAAM-G ankle-stability questionnaires and arthrometer stiffness over 6 months	CAIT and FAAM-G improved versus placebo (both P below .001); arthrometer stiffness unchanged; fewer ankle injuries at 3-month follow-up (P below .05)	Randomised double-blind placebo-controlled trial	29769831
Thymosin beta-4 ophthalmic (RGN-259)	72 subjects with moderate to severe dry eye	Ocular discomfort and corneal fluorescein staining over 28 days	Primary endpoints not significant; central and superior corneal staining improved (P = .0075 and P = .0210) and challenge-model discomfort fell 27 percent at day 28 (P = .0244)	Single-centre double-masked placebo-controlled phase 2 trial	26056426
BPC-157, intravenous	2 adults at a private clinic in Florida, a man of 58 and a woman of 68	Heart, liver, kidney and thyroid biomarkers, blood glucose and side effects	No measurable change in the tested biomarkers and no side effects reported	Open-label safety pilot, single site, three days	40131143
Thymosin beta-4	Mice given a bilateral fibular osteotomy, injected with thymosin beta-4 or saline	Fracture callus strength and mineralised tissue at 21 days	Callus peak force to failure 41 percent higher (p below .01) and about 25 percent stiffer (p below .05) than saline	Controlled mouse fracture study	25042765
Copper tripeptide (GHK-Cu), topical	23 Sprague-Dawley rats with irradiated dorsal skin flaps, 13 test and 10 control	Flap ischaemia, blood vessel number and area, and VEGF over 10 days	No difference in flap ischaemia, vessel number or area, or VEGF versus ointment	Controlled rat wound model	23744835
Copper tripeptide complex, topical	18 New Zealand rabbits with full-thickness open wounds	Unhealed wound area and wound contraction over 21 days	Unhealed area smaller and contraction greater than untreated control on days 7, 14 and 21	Controlled rabbit wound model	17083573

Wound And Ulcer Trials

Two of the human trials above treated diabetic foot ulcers. In the double-blind trial of 216 adults, complete closure over 8 weeks reached 37.3 percent with PDRN against 18.9 percent with placebo, and the median time to close fell from 49 to 30 days (PMID 24483158). A separate randomised study of 20 patients measured tissue oxygenation around the ulcer and found it higher than control at days 7, 14 and 28, though vessel density on histology did not separate (PMID 29076318). A pressure-ulcer trial in 23 patients reported smaller wounds and lower PUSH scores after 4 weeks (PMID 25473213). These are treatment-intent studies in people with a diagnosed condition, so the diabetes and ulcer care they sit inside matters; the therapeutic peptides guide covers approved peptide medicines locally, and the inflammation guide collects the studies on the inflammatory side of repair.

The corneal surface is another wound the record touches. In 72 subjects with moderate to severe dry eye, thymosin beta-4 eye drops missed both primary endpoints but improved central and superior corneal staining and cut challenge-model discomfort by 27 percent at day 28 (PMID 26056426). Background on that peptide sits on the TB-500 page.

Tendon And Ligament Trials

Two families of study appear here. Injected PDRN was tested in refractory rotator cuff disease, where 106 patients saw pain and disability scores improve versus conservative care while strength, range of motion and ultrasonographic tear size did not change (PMID 27914921), and in chronic lateral epicondylitis, where adding PDRN to exercise moved the Mayo Elbow Performance Score and tendon depth more than exercise alone (PMID 34823312). A meta-analysis pooling one randomised and three retrospective studies reported a pain reduction with a standardised mean difference of -1.43 (PMID 34106615). More on the compound sits on the PDRN guide, and the joint-pain angle on the joint pain supplements guide.

Oral collagen peptides were tested with exercise rather than by injection. In a crossover of 20 Achilles tendinopathy patients, VISA-A function rose 12.6 points on collagen against 5.3 on placebo over the first 3 months, both alongside calf-strengthening (PMID 30609761). A trial of 40 patients compared a collagen peptide type-1 combination against oral diclofenac and reported greater pain reduction at 12 weeks (PMID 34812335). In 50 athletes with chronic ankle instability, collagen improved the CAIT and FAAM-G stability questionnaires versus placebo and was followed by fewer ankle injuries, while arthrometer stiffness did not change (PMID 29769831). The collagen peptides guide covers hydrolysis and the type numbers.

The Trial Regimens

The regimens those trials administered, each named with its paper:

PDRN 5.625 mg per 3 mL ampule, intramuscular and perilesional, over 8 weeks in the diabetic foot ulcer trial (PMID 24483158). Specific collagen peptides 5 g daily by mouth for 6 months in the ankle-instability trial (PMID 29769831). Oral specific collagen peptides with a bi-daily calf-strengthening program for 6 months in the Achilles trial (PMID 30609761). Thymosin beta-4 as a 0.1 percent ophthalmic solution over 28 days in the dry eye trial (PMID 26056426).

Disclaimer: these are trial arms reported for comparison, not recommendations and not a titration schedule. Each was administered under medical supervision inside its study, and injectable use in particular is a clinical decision. How injections are handled is covered on the injection guide.

Measured In Animals

Several rows above were run in animals, and their populations say so. Thymosin beta-4 raised fracture-callus peak force to failure 41 percent in mice given a bilateral fibular osteotomy (PMID 25042765). Topical copper tripeptide showed no difference from ointment on irradiated rat skin flaps (PMID 23744835) yet smaller unhealed area than untreated control in rabbit open wounds (PMID 17083573). A result in a mouse callus or a rabbit wound is a result in that animal, and reads across to a person only through further study. The GHK-Cu and BPC-157 pages carry the compound background, and what to check before buying anything sits on the COA verification guide.

How These Records Were Found

Each line states a query, an index and a date. A search result describes what a string matched in one database on one day, nothing beyond that.

polydeoxyribonucleotide AND diabetic foot ulcer in PubMed on 9 August 2026 returned 7 records, among them PMID 24483158 and PMID 29076318.
polydeoxyribonucleotide AND tendinopathy in PubMed on 9 August 2026 returned 7 records.
collagen peptide AND achilles tendinopathy AND randomized in PubMed on 9 August 2026 returned 8 records.
thymosin beta 4 AND wound healing AND randomized in PubMed on 9 August 2026 returned 8 records; the retrieved dry eye trial PMID 26056426 measured corneal staining.
copper tripeptide AND wound healing in PubMed on 9 August 2026 returned 33 records; the ones read here, PMID 23744835 and PMID 17083573, were rat and rabbit models.
BPC 157 AND clinical trial[pt] in PubMed on 9 August 2026 returned 0 records; the publication tag is the boundary of that count, and PMID 40131143 carries no such tag.
A compound name bounds a search, so synonyms and MeSH entry terms were tried where known: PDRN as polydeoxyribonucleotide, GHK-Cu as copper tripeptide, and thymosin beta-4 as Tbeta4 and RGN-259.

Frequently Asked Questions

What are the best peptides for injury healing?+

This page does not rank them. It reports what each cited study enrolled, what it measured and what it found, so a foot-ulcer closure in 216 adults and a biomarker panel in 2 adults can be told apart. Reading the population column first shows which claims were measured in people and which were measured in rats, rabbits or mice.

Does an ulcer-healing result apply to a torn tendon or muscle?+

Not automatically. The diabetic foot ulcer trial (PMID 24483158) produced a result in Wagner grade 1 or 2 diabetic foot ulcers, and the rotator cuff study (PMID 27914921) produced a result in chronic refractory rotator cuff disease. These are different tissues, different injuries and different patients, so each number applies to the population its trial enrolled and nowhere else without separate study.

What is the human record for BPC-157 in injury repair?+

The BPC-157 study cited here is a three-day safety pilot in 2 adults given intravenous BPC-157 at a private clinic (PMID 40131143). It measured heart, liver, kidney, thyroid and glucose markers and side effects, not tendon or wound healing, and reported no measurable change and no side effects. The search line in the provenance section records what the clinical-trial publication tag returned for this compound. Background on the molecule sits on the BPC-157 page.

Why do some rows say rat, rabbit or mouse?+

Because a row is a study and its population is whoever the study enrolled. The GHK-Cu flap work (PMID 23744835) was done in irradiated rats and reported no difference from ointment; the copper tripeptide open-wound work (PMID 17083573) was in rabbits; the fracture study (PMID 25042765) was in mice. Those results describe rats, rabbits and mice, and the design column says so.

What is PDRN and how was it given in these trials?+

Polydeoxyribonucleotide is a mix of deoxyribonucleotide polymers described by the diabetic foot ulcer authors as an adenosine A2A receptor agonist (PMID 24483158). In the trials above it was injected, intramuscularly and around the lesion in the ulcer studies and around the tendon in the musculoskeletal studies, rather than swallowed. More on the compound sits on the PDRN guide.

What did the collagen tendinopathy trials actually measure?+

They measured questionnaires and imaging alongside exercise. The Achilles crossover (PMID 30609761) tracked the VISA-A tendon-function score and tendon microvascularity while patients did a calf-strengthening program. The ankle-instability trial (PMID 29769831) tracked the CAIT and FAAM-G stability questionnaires and arthrometer stiffness. The questionnaires moved; the arthrometer stiffness did not.

Should someone use these to treat an injury on their own?+

A wound, an ulcer, a torn tendon or an unstable ankle is diagnosed and managed with a clinician. Every regimen above was administered inside a trial under medical supervision, and a diabetic foot ulcer in particular is a condition where delay carries real risk. Take the population and the endpoint to a doctor, not a compound name off a label.

Research And Sources

Every figure above comes from the record its PMID links to, retrieved through NCBI E-utilities on 9 August 2026. The diabetic foot ulcer healing rates and hazard ratio come from PMID 24483158, the collagen VISA-A change from PMID 30609761, and the corneal staining and discomfort figures from PMID 26056426. The provenance section records what each search returned, including the clinical-trial-tag counts, rather than the body claiming anything about what does or does not exist.